249 related articles for article (PubMed ID: 32217102)
1. The inhibitory effect of ECG and EGCG dimeric procyanidins on colorectal cancer cells growth is associated with their actions at lipid rafts and the inhibition of the epidermal growth factor receptor signaling.
Zhu W; Li MC; Wang FR; Mackenzie GG; Oteiza PI
Biochem Pharmacol; 2020 May; 175():113923. PubMed ID: 32217102
[TBL] [Abstract][Full Text] [Related]
2. NADPH oxidase 1: A target in the capacity of dimeric ECG and EGCG procyanidins to inhibit colorectal cancer cell invasion.
Zhu W; Oteiza PI
Redox Biol; 2023 Sep; 65():102827. PubMed ID: 37516013
[TBL] [Abstract][Full Text] [Related]
3. The inhibitory effect of (-)-epigallocatechin gallate on activation of the epidermal growth factor receptor is associated with altered lipid order in HT29 colon cancer cells.
Adachi S; Nagao T; Ingolfsson HI; Maxfield FR; Andersen OS; Kopelovich L; Weinstein IB
Cancer Res; 2007 Jul; 67(13):6493-501. PubMed ID: 17616711
[TBL] [Abstract][Full Text] [Related]
4. Hexameric procyanidins inhibit colorectal cancer cell growth through both redox and non-redox regulation of the epidermal growth factor signaling pathway.
Daveri E; Adamo AM; Alfine E; Zhu W; Oteiza PI
Redox Biol; 2021 Jan; 38():101830. PubMed ID: 33338921
[TBL] [Abstract][Full Text] [Related]
5. (-)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells.
Shimizu M; Deguchi A; Lim JT; Moriwaki H; Kopelovich L; Weinstein IB
Clin Cancer Res; 2005 Apr; 11(7):2735-46. PubMed ID: 15814656
[TBL] [Abstract][Full Text] [Related]
6. The PI3K/Akt pathway is involved in procyanidin-mediated suppression of human colorectal cancer cell growth.
Choy YY; Fraga M; Mackenzie GG; Waterhouse AL; Cremonini E; Oteiza PI
Mol Carcinog; 2016 Dec; 55(12):2196-2209. PubMed ID: 26774105
[TBL] [Abstract][Full Text] [Related]
7. Epigallocatechin-3-gallate inhibits epidermal growth factor receptor signaling pathway. Evidence for direct inhibition of ERK1/2 and AKT kinases.
Sah JF; Balasubramanian S; Eckert RL; Rorke EA
J Biol Chem; 2004 Mar; 279(13):12755-62. PubMed ID: 14701854
[TBL] [Abstract][Full Text] [Related]
8. A-type ECG and EGCG dimers inhibit 3T3-L1 differentiation by binding to cholesterol in lipid rafts.
Zhu W; Deng X; Peng J; Zou B; Li C
J Nutr Biochem; 2017 Oct; 48():62-73. PubMed ID: 28772148
[TBL] [Abstract][Full Text] [Related]
9. (-)-Epigallocatechin gallate inhibits growth and activation of the VEGF/VEGFR axis in human colorectal cancer cells.
Shimizu M; Shirakami Y; Sakai H; Yasuda Y; Kubota M; Adachi S; Tsurumi H; Hara Y; Moriwaki H
Chem Biol Interact; 2010 May; 185(3):247-52. PubMed ID: 20346928
[TBL] [Abstract][Full Text] [Related]
10. Epigallocatechin-3-gallate (EGCG) downregulates EGF-induced MMP-9 in breast cancer cells: involvement of integrin receptor α5β1 in the process.
Sen T; Chatterjee A
Eur J Nutr; 2011 Sep; 50(6):465-78. PubMed ID: 21170718
[TBL] [Abstract][Full Text] [Related]
11. A green tea component suppresses posttranslational expression of basic fibroblast growth factor in colorectal cancer.
Sukhthankar M; Yamaguchi K; Lee SH; McEntee MF; Eling TE; Hara Y; Baek SJ
Gastroenterology; 2008 Jun; 134(7):1972-80. PubMed ID: 18549879
[TBL] [Abstract][Full Text] [Related]
12. The Effect of Different Treatments of (-)-Epigallocatechin-3-Gallate on Colorectal Carcinoma Cell Lines.
Ding YP; Gao ZL; Chen BC; Rakariyatham K; Suo HY; Tong HR; Xiao H
Nutr Cancer; 2018 Oct; 70(7):1126-1136. PubMed ID: 30513211
[TBL] [Abstract][Full Text] [Related]
13. Proliferation of MDA-MB-231 can be suppressed by dimeric-epigallocatechin gallate through competitive inhibition of amphiregulin-epidermal growth factor receptor signaling.
Huang Y; Zhang X; Pang Q; Zhu Q; Liang Q; Zi C; Zhang D; Xiang Z; Wang X; Sheng J
Anticancer Drugs; 2021 Jun; 32(6):647-656. PubMed ID: 33587351
[TBL] [Abstract][Full Text] [Related]
14. Lipid rafts mediate epigallocatechin-3-gallate- and green tea extract-dependent viability of human colon adenocarcinoma COLO 205 cells; clusterin affects lipid rafts-associated signaling pathways.
Pajak B; Kania E; Gajkowska B; Orzechowski A
J Physiol Pharmacol; 2011 Aug; 62(4):449-59. PubMed ID: 22100846
[TBL] [Abstract][Full Text] [Related]
15. Synergistic inhibition of head and neck tumor growth by green tea (-)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor.
Zhang X; Zhang H; Tighiouart M; Lee JE; Shin HJ; Khuri FR; Yang CS; Chen Z'; Shin DM
Int J Cancer; 2008 Sep; 123(5):1005-14. PubMed ID: 18546267
[TBL] [Abstract][Full Text] [Related]
16. (-)-Epigallocatechin gallate downregulates EGF receptor via phosphorylation at Ser1046/1047 by p38 MAPK in colon cancer cells.
Adachi S; Shimizu M; Shirakami Y; Yamauchi J; Natsume H; Matsushima-Nishiwaki R; To S; Weinstein IB; Moriwaki H; Kozawa O
Carcinogenesis; 2009 Sep; 30(9):1544-52. PubMed ID: 19578043
[TBL] [Abstract][Full Text] [Related]
17. Epigallocatechin-3-gallate decreases VEGF production in head and neck and breast carcinoma cells by inhibiting EGFR-related pathways of signal transduction.
Masuda M; Suzui M; Lim JT; Deguchi A; Soh JW; Weinstein IB
J Exp Ther Oncol; 2002; 2(6):350-9. PubMed ID: 12440226
[TBL] [Abstract][Full Text] [Related]
18. The polyphenol epigallocatechin-3-gallate affects lipid rafts to block activation of the c-Met receptor in prostate cancer cells.
Duhon D; Bigelow RL; Coleman DT; Steffan JJ; Yu C; Langston W; Kevil CG; Cardelli JA
Mol Carcinog; 2010 Aug; 49(8):739-49. PubMed ID: 20623641
[TBL] [Abstract][Full Text] [Related]
19. Targeting receptor tyrosine kinases for chemoprevention by green tea catechin, EGCG.
Shimizu M; Shirakami Y; Moriwaki H
Int J Mol Sci; 2008 Jun; 9(6):1034-1049. PubMed ID: 19325845
[TBL] [Abstract][Full Text] [Related]
20. (-)-Epigallocatechin gallate causes internalization of the epidermal growth factor receptor in human colon cancer cells.
Adachi S; Nagao T; To S; Joe AK; Shimizu M; Matsushima-Nishiwaki R; Kozawa O; Moriwaki H; Maxfield FR; Weinstein IB
Carcinogenesis; 2008 Oct; 29(10):1986-93. PubMed ID: 18586691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
